Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Bernadette M. Cuello"'
Autor:
Anthony F. Daniyan, Maximilian Stahl, Martin S. Tallman, Alexander Chan, Aaron D. Viny, Sheng F. Cai, Christopher Famulare, Eytan M. Stein, Kamal Menghrajani, Jacob L. Glass, Bernadette M. Cuello, Mikhail Roshal, Omar Abdel-Wahab, Troy Z. Horvat, Aaron D. Goldberg, Andriy Derkach, Amber C. King, Wenbin Xiao, Ross L. Levine
Publikováno v:
Blood Adv
Azacitidine + venetoclax, decitabine + venetoclax, and low-dose cytarabine + venetoclax are now standard treatments for newly diagnosed older or unfit patients with acute myeloid leukemia (AML). Although these combinations are also commonly used in r
Autor:
Andriy Derkach, Doris M. Ponce, Jacob L. Glass, Maximilian Stahl, Amber C. King, Jan Philipp Bewersdorf, Brian C. Shaffer, Sergio Giralt, Roni Tamari, Miguel-Angel Perales, Kamal Menghrajani, Boglarka Gyurkocza, Ann A. Jakubowski, Lohith Gowda, Susan DeWolf, Aaron D. Goldberg, Amer M. Zeidan, Stuart Seropian, Martin S. Tallman, Alexander Chan, Christopher Famulare, Eytan M. Stein, Anthony F. Daniyan, Josel D. Ruiz, Thomas Prebet, Bernadette M. Cuello, Wenbin Xiao, Mikhail Roshal, Christina Cho, Nikolai A. Podoltsev, Sheng F. Cai, James W. Young
Publikováno v:
Leuk Lymphoma
The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid leukemia (AML) are unclear. We
Autor:
Susan DeWolf, Kamal Menghrajani, Josel D. Ruiz, Brian C. Shaffer, Bernadette M. Cuello, Ann A. Jakubowski, Boglarka Gyurkocza, Alexander Chan, Aaron D Goldberg, Wenbin Xiao, Mikhail Roshal, Doris M. Ponce, Martin S. Tallman, Christina Cho, Jacob L. Glass, Maximilian Stahl, Anthony F. Daniyan, Andriy Derkach, Roni Tamari, Amber C. King, Troy Z. Horvat, Miguel-Angel Perales, Sergio Giralt, James W. Young, Juliet N. Barker, Sheng F. Cai, Christopher Famulare, Eytan M. Stein
Publikováno v:
Blood. 136:16-17
Background: Venetoclax (ven) combined with azacitidine (aza/ven), decitabine (dec/ven), and low-dose cytarabine (LDAC/ven) is approved as frontline therapy for older or otherwise unfit AML patients (pts) and also frequently used for pts with relapsed
Autor:
Kamal Menghrajani, Ross L. Levine, Christopher Famulare, Eytan M. Stein, Martin S. Tallman, Bernadette M. Cuello, Wenbin Xiao, Aaron D Goldberg, Andriy Derkach, Jacob L. Glass, Anthony F. Daniyan, Omar Abdel-Wahab, Mikhail Roshal, Alexander Chan, Maximilian Stahl, Aaron D. Viny, Amber C. King
Publikováno v:
Blood. 136:47-48
Background: Venetoclax combined with azacitidine (aza/ven), decitabine (dec/ven), and low-dose cytarabine (LDAC/ven) is commonly used off-label in relapsed/refractory (RR)-AML patients; however, predictors of response and survival are incompletely un
Autor:
Bernadette M. Cuello
Publikováno v:
Biology of Blood and Marrow Transplantation. 19:S357-S358
Autor:
Susan E. Prockop, Andromachi Scaradavou, Bernadette M. Cuello, James W. Young, Esperanza B. Papadopoulos, Nancy A. Kernan, Hugo Castro-Malaspina, Joanne Taylor, Farid Boulad, Trudy N. Small, Richard J. O'Reilly, Ruth Ford
Publikováno v:
Blood. 112:2214-2214
The incidence of pertussis in the United States has steadily increased over the last decade particularly in adolescents and adults. In 2005, in an effort to reduce pertussis in these populations, two vaccines containing tetanus, reduced diphtheria an